Searching for MODY in general practitioner’s surgery
Authors:
J. Urbanová 1; L. Brunerová 1; J. Brož
Authors‘ workplace:
Diabetologické centrum
II. interní klinika 3. LF UK a FNKV, Praha
Přednosta: prof. MUDr. Michal Kršek, CSc.
1; Interní klinika 2. LF UK a FN Motol, Praha
Přednosta: prof. MUDr. Milan Kvapil, CSc., MBA
2
Published in:
Prakt. Lék. 2018; 98(4): 153-157
Category:
Various Specialization
Overview
General Practitioner’s surgery is the place where diabetes is diagnosed probably the most often. In case of MODY (Maturity Onset Diabetes of the Young) this is true more likely due to its characteristic features – diabetes onset in early age (before the age of 25 years) and usually mild hyperglycaemia. Despite a growing awareness of this relatively common type of diabetes, up to 90% of patients are classified incorrectly and remain hidden for a long time or permanently under the diagnosis of other types of diabetes, especially type 1 or 2. The aim of this article is to summarize the diagnostic criteria of MODY to help its early diagnosis, especially in those MODY patients concealed under the previously mislabelled type of diabetes..
Keywords:
MODY – diagnosis – differential diagnosis
Sources
1. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care 2011; 34: 1878–1884.
2. Online Mendelian Inheritance in Man. Maturity-onset diabetes of the young; MODY [online]. Dostupné z: https://www.omim.org/entry/606391 [cit. 6-6-2018].
3. Shields BM, Hicks S, Shepherd MH, et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010; 53(12): 2504–2508.
4. Shepherd M, Miles S, Jones J, et al. Differential diagnosis: Identifying people with monogenic diabetes. J Diabetes Nurs 2010; 14(9): 342–347.
5. Byrne MM, Sturis J, Clement K, et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest 1994; 93(3): 1120–1130.
6. Steele AM, Wensley KJ, Ellard S, et al. Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies. PLoS One 2013; 8: e65326.
7. Stride A, Shields B, Gill-Carey O, et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia 2014; 57(1): 54–56.
8. Ellard S, Bellanné-Chantelot C, Hattersley AT, European Molecular Genetics Quality Network (EMQN) MODY group. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008; 51(4): 546–553.
9. Chakera AJ, Steele AM, Gloyn AL, et al. Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. Diabetes Care 2015; 38(7): 1383–1392.
10. Stride A, Vaxillaire M, Tuomi T, et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 2002; 45(3): 427–435.
11. Pearson ER, Liddell WG, Shepherd M, et al. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diab Med 2000; 17(7): 543–545.
12. Isomaa B, Henricsson M, Lehto M, et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia 1998; 41(4): 467–473.
13. Shields BM, Shepherd M, Hudson M, et al. Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients. Diabetes Care 2017; 40(8): 1017–1025.
14. Grzanka M, Matejko B, Szopa M, et al. Assessment of newly proposed clinical criteria to identify HNF1A MODY in patients with an initial diagnosis of type 1 or type 2 diabetes mellitus. Adv Med 2016; 2016: 4243784.
15. Slingerland AS. Monogenic diabetes in children and young adults: challenges for researcher, clinician and patient. Rev Endocr Metab Disord 2006; 7: 171–185.
16. McDonald TJ, Shields BM, Lawry J, et al. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. Diabetes Care 2011; 34(8): 1860–1862.
17. Owen KR, Shepherd M, Stride A, et al. Heterogeneity in young adult onset aetiology alters clinical characteristics. Diabet Med 2002; 19(9): 758–761.
18. McDonald TJ, McEneny J, Pearson ER, et al. Lipoprotein composition in HNF1A-MODY: Differentiating between HNF1A-MODY and Type 2 diabetes. Clin Chim Acta 2012, 413(9–10): 927–932.
19. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic β-cell diabetes. Nat Clin Pract Endocrinol Metab 2008; 4(4): 200–213.
20. Pearson ER, Boj SF, Steele AM, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med 2007; 4(4): e118.
21. Edghill EL, Bingham C, Slingerland AS, et al. Hepatocyte nuclear factor-1 beta mutations cause neonatal diabetes and intrauterine growth retardation: support for a critical role of HNF-1beta in human pancreatic development. Diabet Med 2006; 23(12): 1301–1306.
22. Chen YZ, Gao Q, Zhao XZ, et al. Systematic review of TCF2 anomalies in renal cysts and diabetes syndrome/maturity onset diabetes of the young type 5. Chin Med J (Engl). 2010; 123(22): 3326–3333.
23. Adalat S, Woolf AS, Johnstone KA, et al. HNF1B mutations associate with hypomagnesemia and renal magnesium wasting. J Am Soc Nephrol 2009; 20(5): 1123–1131.
24. Thanabalasingham G, Pal A, Selwood MP, et al. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care 2012; 35(6): 1206–1212.
25. Bellanné-Chantelot C, Carette C, Riveline JP, et al. The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. Diabetes 2008; 57(2): 503–508.
26. Lango Allen H, Johansson S, Ellard S et al. Polygenic risk variants for type 2 diabetes susceptibility modify age at diagnosis in monogenic HNF1A diabetes. Diabetes 2010; 59(1): 266–271.
27. Stride A, Shepherd M, Frayling TM, et al. Intrauterine hyperglycemia is associated with an earlier diagnosis of diabetes in HNF-1α gene mutation carriers. Diabetes Care 2002; 25: 2287–2291.
28. Klupa T, Warram JH, Antonellis A, et al. Determinants of the development of diabetes (maturity-onset diabetes of the young-3) in carriers of HNF-1α mutations: evidence for parent-of-origin effect. Diabetes Care 2002; 25(12): 2292–2301.
29. Stanik J, Dusatkova P, Cinek O, et al. De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed. Diabetologia 2014; 57(3): 480–484.
30. Schober E, Rami B, Grabert M, et al. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicenter database. Diabet Med 2009; 26(5): 466–473.
31. Urbanová J, Rypáčková B, Procházková Z, et al. Positivity for islet cell autoantibodies in patients with monogenic diabetes is associated with later diabetes onset and higher HbA1c level. Diabet Med 2014; 31(4): 466–471.
32. Průhová Š, Dušátková P, Neumann D, et al. Two cases of diabetic ketoacidosis in HNF1A-MODY linked to severe dehydration: is it time to change the diagnostic criteria for MODY? Diabetes Care 2013; 36(9): 2573–2574
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2018 Issue 4
Most read in this issue
- Endometriosis and its effect on fertility and quality of life – literature review
- Imaging methods in pregnancy – indications and contraindications and use of contrast media
- Disability pension against social stress?
- The importance of gait as the most natural physical activity in the human life style